Kolexia
Sabatier Renaud
Oncologie médicale
Centre Paoli-Calmettes
Marseille, France
212 Activités
200 Followers

Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Tumeurs de l'endomètre Carcinomes Tumeurs de l'ovaire Tumeurs du sein triple-négatives Métastase tumorale Tumeurs du poumon Instabilité des microsatellites Récidive tumorale locale

Industries

A+A
24 collaboration(s)
Dernière en 2023
GSK
22 collaboration(s)
Dernière en 2023
KEPHREN
6 collaboration(s)
Dernière en 2023
EXAFIELD
5 collaboration(s)
Dernière en 2022

Dernières activités

CUPCAKE: Early Detection of Triple Negative Breast Cancer Relapse: a Clinical Utility Phase II Trial
Essai Clinique (Institut Curie)   06 mars 2024
DOMENICA: Randomized Phase III Trial in MMR Deficient Endometrial Cancer Patients Comparing Chemotherapy Alone Versus Dostarlimab in First Line Advanced/Metastatic Setting
Essai Clinique (GSK)   28 février 2024
AcSé CRIZOTINIB : Secured Access to Crizotinib for Patients With Tumors Harboring a Genomic Alteration on One of the Biological Targets of the Drug.
Essai Clinique (Unicancer)   26 février 2024
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.
The New England journal of medicine   15 décembre 2023
TEDOVA: Randomized Phase II Study Comparing Neo-epitope Based Vaccine OSE2101 (TEDOPI®) With or Without Anti-PD1 (Pembrolizumab) Versus Best Supportive Care as Maintenance Treatment in Platinum-sensitive Recurrent Ovarian Cancer Patient With Controlled Disease After Platinum-based Chemotherapy
Essai Clinique (Merck & Co.)   04 décembre 2023
22P Predictive value of tertiary lymphoid structure in patients with mismatch repair deficient advanced/recurrent endometrial cancer treated with dostarlimab
Abstract Book of the ESMO Immuno-Oncology Congress 2023 6-8 December 2023   01 décembre 2023
Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled Trial.
JAMA network open   01 novembre 2023
MOIO : étude de phase III multicentrique prospective évaluant la décroissance thérapeutique de l’immunothérapie chez des patients répondeurs ayant un cancer métastatique
Edimark   31 octobre 2023
796P Initial management and long-term outcome of advanced low-grade serous ovarian cancer (LGSOC) exploring role of surgery and maintenance therapy in the French multicentre ESME database
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
PADA-1: Randomized, Open Label, Multicentric Phase III Trial to Evaluate the Safety and Efficacy of Palbociclib in Combination With HT Driven by ctDNA ESR1 Mutation Monitoring in ER+, HER2-negative Metastatic Breast Cancer Patients
Essai Clinique (Pfizer)   21 septembre 2023